{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T06:09:07Z","timestamp":1790834947932,"version":"4.1.0"},"reference-count":19,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T00:00:00Z","timestamp":1248307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust J Dermatology"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>The present study was undertaken to compare the efficacy and safety of thalidomide to that of oral prednisolone in the treatment of moderate to severe type 2 lepra reaction. Sixty patients with a histologically confirmed diagnosis of erythema nodosum leprosum with a clinical score of 4 or more (i.e. moderate to severe type 2 reaction) were randomly allocated to two groups comprising 30 patients each. Group 1 patients were given thalidomide at a dose of 300\u2003mg\/day for 1\u2003week and the dose was gradually reduced, and Group 2 received prednisolone 40\u2003mg daily for 2\u2003weeks, which was tapered by 10\u2003mg every 2\u2003weeks. Thalidomide induced a faster clinical response (cutaneous as well as systemic) compared with prednisolone. Patients taking thalidomide had fewer relapses and a longer period of remission than those receiving prednisolone.<\/jats:p>","DOI":"10.1111\/j.1440-0960.2009.00534.x","type":"journal-article","created":{"date-parts":[[2009,7,23]],"date-time":"2009-07-23T04:45:58Z","timestamp":1248324358000},"page":"181-185","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Comparative efficacy of thalidomide and prednisolone in the treatment of moderate to severe erythema nodosum leprosum: A randomized study"],"prefix":"10.1111","volume":"50","author":[{"given":"Inderjeet","family":"Kaur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunil","family":"Dogra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarun","family":"Narang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipankar","family":"De","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2009,7,23]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"253","article-title":"The management of erythema nodosum leprosum: current and future options","volume":"67","author":"Lockwood DN.","year":"1996","journal-title":"Lepr. Rev."},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1489\/1544-581X(2004)072<0125:ECOLRY>2.0.CO;2"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/168.2.408"},{"key":"e_1_2_6_5_2","first-page":"286","article-title":"The return of thalidomide: new uses and renewed concerns","volume":"74","author":"Pannikar V.","year":"2003","journal-title":"Lepr. Rev."},{"key":"e_1_2_6_6_2","first-page":"290","article-title":"The return of thalidomide: new uses and renewed concerns: reply","volume":"74","author":"Lockwood DN","year":"2003","journal-title":"Lepr. Rev."},{"key":"e_1_2_6_7_2","first-page":"288","article-title":"On thalidomide and WHO policies: reply","volume":"74","author":"Pereira GF.","year":"2003","journal-title":"Lepr. Rev."},{"key":"e_1_2_6_8_2","first-page":"497","article-title":"Treatment of steroid dependant cases of recurrent lepra reaction with a combination of thalidomide and clofazamine","volume":"51","author":"Ramu G","year":"1979","journal-title":"Lepr. India"},{"key":"e_1_2_6_9_2","first-page":"309","article-title":"Leprosy: global situation","volume":"81","author":"World Health Organization","year":"2006","journal-title":"Wkly Epidemiol. Rec."},{"key":"e_1_2_6_10_2","first-page":"8","article-title":"Clinical features and outcome of reversal (type 1) reactions in Hyderabad, India","author":"Lockwood DN","year":"1993","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"e_1_2_6_11_2","first-page":"S21","article-title":"Treatment of reactions and nerve damage","volume":"64","author":"Naafs B.","year":"1996","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"e_1_2_6_12_2","first-page":"719","article-title":"WHO co\u2010ordinated short term double blind trial with thalidomide in the treatment of acute lepra reactions in male lepromatous patients","volume":"45","author":"Iyer CG","year":"1971","journal-title":"Bull. World Health Organ."},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2005.72.518"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1085-5629(98)80019-9"},{"key":"e_1_2_6_15_2","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1590\/S0100-879X2007000200011","article-title":"Double\u2010blind trial of the efficacy of pentoxifylline vs thalidomide for the treatment of type 2 reaction in leprosy","volume":"40","author":"Sales AM","year":"2007","journal-title":"Braz. J. Med. Biol. Res."},{"key":"e_1_2_6_16_2","first-page":"61","article-title":"Comparison of pentoxifylline, thalidomide and prednisone in the treatment of ENL","volume":"66","author":"Andre L","year":"1998","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"e_1_2_6_17_2","first-page":"10","article-title":"Leprosy reactions \u2013 complications of steroid therapy","volume":"66","author":"Sugumaran DS.","year":"1998","journal-title":"Int. J. Lepr. Other Mycobact. Dis."},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(96)90122-X"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.1109"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1994.01690010070009"}],"updated-by":[{"DOI":"10.1111\/j.1440-0960.2009.00572.x","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2009,11,4]],"date-time":"2009-11-04T00:00:00Z","timestamp":1257292800000}}],"container-title":["Australasian Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1440-0960.2009.00534.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1440-0960.2009.00534.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T11:36:40Z","timestamp":1697456200000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1440-0960.2009.00534.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,7,23]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1440-0960.2009.00534.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1440-0960.2009.00534.x","archive":["Portico"],"relation":{},"ISSN":["0004-8380","1440-0960"],"issn-type":[{"value":"0004-8380","type":"print"},{"value":"1440-0960","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,7,23]]},"assertion":[{"value":"2009-07-23","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}